Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

Fig. 1

a–c Effects of secukinumab on signs of MRI inflammation in psoriasis patients at risk to develop PsA. T2-weighted coronal fat saturated (TIRM) sequences of the hands of psoriasis patients at risk to develop PsA. Three examples, one from metacarpophalangeal joints and two from the wrist joint, are shown. Left column: overview at baseline; middle column: close-up of the inflammatory lesion at baseline; right column: follow-up of the same region after 24 weeks of secukinumab treatment. Black arrows mark the lesion; white frames mark the area depicted in the close-up

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us